Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

Table 4

Healthcare utilization during follow-up period among HER2-targeted agent subgroups.

	HT−	HT+	De novo	Recurrent	AGE 18–44	AGE 45–64	AGE 65+
	= 1,272	= 1,357		= 1,654		= 1,801
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
All-cause monthly utilization
Inpatient admissions	0.20 (0.90)	0.09 (0.23)^a	0.11 (0.38)	0.16 (0.77)^c	0.10 (0.25)	0.16 (0.76)	0.12 (0.33)
Total inpatient days	1.00 (2.92)	0.50 (1.53)^a	0.62 (2.08)	0.81 (2.45)^c	0.52 (1.64)	0.80 (2.52)	0.69 (1.98)
Outpatient utilization	17.95 (12.33)	15.57 (10.23)^a	17.71 (11.19)	16.14 (11.42)^b	17.53 (11.47)	17.11 (11.06)	14.28 (12.16)^a
Emergency department (ED) visits	0.17 (0.70)	0.08 (0.21)^a	0.09 (0.26)	0.14 (0.61)^b	0.11 (0.32)	0.12 (0.57)	0.15 (0.38)
Outpatient office visits	2.03 (1.27)	1.85 (1.07)^a	2.05 (1.15)	1.87 (1.18)^a	2.05 (1.38)	1.92 (1.14)	1.90 (1.10)
Radiation treatment^d	3.25 (6.08)	2.86 (5.04)	3.17 (4.54)	2.98 (6.10)	3.15 (5.15)	3.10 (5.62)	2.75 (5.76)
Diagnostic radiology^d	2.34 (2.78)	2.01 (1.95)^b	2.35 (2.72)	2.06 (2.17)^b	2.25 (2.02)	2.20 (2.41)	1.96 (2.61)
Laboratory services	5.62 (5.57)	4.94 (4.50)^b	5.71 (5.26)	5.01 (4.91)^b	6.19 (5.32)	5.61 (4.95)	2.95 (4.57)^a
Other outpatient care^e	4.53 (3.58)	3.82 (2.54)^a	4.33 (3.26)	4.07 (3.01)^c	3.77 (2.16)	4.16 (2.91)	4.57 (4.39)^b
Prescription fills	3.08 (2.51)	3.25 (2.32)	3.14 (2.33)	3.18 (2.47)	2.83 (2.35)	3.17 (2.39)	3.46 (2.54)^b
Breast cancer monthly utilization
Inpatient admissions	0.02 (0.08)	0.01 (0.03)^b	0.02 (0.06)	0.01 (0.06)^a	0.01 (0.05)	0.01 (0.06)	0.01 (0.04)
Total inpatient days	0.12 (0.98)	0.04 (0.20)^b	0.10 (0.91)	0.06 (0.53)	0.04 (0.24)	0.09 (0.80)	0.04 (0.47)
Outpatient utilization	11.80 (9.52)	10.24 (8.07)^a	12.58 (8.96)	10.07 (8.63)^a	12.28 (9.88)	11.35 (8.30)	8.31 (9.46)^a
Emergency department (ED) visits	0.04 (0.20)	0.02 (0.15)^c	0.02 (0.15)	0.03 (0.19)	0.04 (0.21)	0.02 (0.16)	0.03 (0.19)
Outpatient office visits	1.47 (1.12)	1.25 (0.90)^a	1.51 (1.02)	1.27 (1.00)^a	1.48 (1.27)	1.36 (0.97)	1.24 (0.90)^b
Radiation treatment^d	1.90 (4.66)	1.72 (3.74)	2.24 (3.64)	1.55 (4.50)^a	2.08 (4.55)	1.84 (4.16)	1.43 (4.08)
Diagnostic radiology^d	1.39 (1.83)	1.21 (1.63)^b	1.55 (1.91)	1.15 (1.60)^a	1.48 (1.73)	1.33 (1.72)	0.98 (1.75)^a
Laboratory services	4.15 (4.40)	3.71 (3.84)^b	4.39 (4.41)	3.65 (3.92)^a	4.71 (4.38)	4.16 (3.98)	2.18 (4.04)^a
Other outpatient care^e	2.81 (2.71)	2.30 (1.72)^a	2.82 (2.66)	2.38 (1.98)^a	2.46 (1.65)	2.60 (2.07)	2.42 (3.32)
Office-administered antineoplastic agents	0.04 (0.16)	0.05 (0.13)	0.05 (0.15)	0.04 (0.15)	0.04 (0.14)	0.05 (0.15)	0.04 (0.14)
Outpatient pharmacy antineoplastic agents	0.12 (0.25)	0.41 (0.37)^b	0.25 (0.29)	0.28 (0.38)^c	0.33 (0.36)	0.27 (0.35)	0.24 (0.34)^b

value compared to corresponding HER2-targeted agent subgroup(s) <0.0001.
value compared to corresponding HER2-targeted agent subgroup(s) <0.01.
value compared to corresponding HER2-targeted agent subgroup(s) <0.05.
^dRadiation treatment and diagnostic radiology encompass all outpatient radiology services during follow-up.
^eOther outpatient care includes all remaining outpatient services that are not reported individually.
^fPatient’s monthly utilization is calculated using the following formula: (patient’s total number visits or claims/patient’s total days of follow-up) * 30 days.